Tight junction and kidney stone disease

References

• Otani T, Furuse M. Tight junction structure and function revisited. Trends Cell Biol. 2020;30(10):48–63. doi:10.1016/j.tcb.2020.08.004.
   Web of Science ®Google Scholar
• Liang GH, Weber CR. Molecular aspects of tight junction barrier function. Curr Opin Pharmacol. 2014;19:84–89. doi:10.1016/j.coph.2014.07.017.
   PubMed Web of Science ®Google Scholar
• Zihni C, Mills C, Matter K, Balda MS. Tight junctions: from simple barriers to multifunctional molecular gates. Nat Rev Mol Cell Biol. 2016;17(9):564–580. doi:10.1038/nrm.2016.80.
   PubMed Web of Science ®Google Scholar
• Odenwald MA, Choi W, Buckley A, Shashikanth N, Joseph NE, Wang Y, Warren MH, Buschmann MM, Pavlyuk R, Hildebrand J, et al. ZO-1 interactions with F-actin and occludin direct epithelial polarization and single lumen specification in 3D culture. J Cell Sci. 2017;130:243–259. doi:10.1242/jcs.188185.
   PubMed Web of Science ®Google Scholar
• Glotfelty LG, Zahs A, Iancu C, Shen L, Hecht GA. Microtubules are required for efficient epithelial tight junction homeostasis and restoration. Am J Physiol Cell Physiol. 2014;307(3):C245–54. doi:10.1152/ajpcell.00336.2013.
   PubMed Web of Science ®Google Scholar
• Alelign T, Petros B. Kidney stone disease: an update on current concepts. Adv Urol. 2018;2018:3068365. doi:10.1155/2018/3068365.
   PubMed Web of Science ®Google Scholar
• Viljoen A, Chaudhry R, Bycroft J. Renal stones. Ann Clin Biochem. 2019;56(1):15–27. doi:10.1177/0004563218781672.
   PubMed Web of Science ®Google Scholar
• Thongprayoon C, Krambeck AE, Rule AD. Determining the true burden of kidney stone disease. Nat Rev Nephrol. 2020;16(12):736–746. doi:10.1038/s41581-020-0320-7.
   PubMed Web of Science ®Google Scholar
• Lang J, Narendrula A, El-Zawahry A, Sindhwani P, Ekwenna O. Global trends in incidence and burden of urolithiasis from 1990 to 2019: an analysis of global burden of disease study data. Eur Urol Open Sci. 2022;35:37–46. doi:10.1016/j.euros.2021.10.008.
   PubMedGoogle Scholar
• Wang K, Ge J, Han W, Wang D, Zhao Y, Shen Y, Chen J, Chen D, Wu J, Shen N, et al. Risk factors for kidney stone disease recurrence: a comprehensive meta-analysis. BMC Urol. 2022;22(1):62. doi:10.1186/s12894-022-01017-4.
   PubMed Web of Science ®Google Scholar
• Moftakhar L, Jafari F, Ghoddusi Johari M, Rezaeianzadeh R, Hosseini SV, Rezaianzadeh A. Prevalence and risk factors of kidney stone disease in population aged 40–70 years old in Kharameh cohort study: a cross-sectional population-based study in southern Iran. BMC Urol. 2022;22(1):205. doi:10.1186/s12894-022-01161-x.
   PubMed Web of Science ®Google Scholar
• Zeng J, Wang S, Zhong L, Huang Z, Zeng Y, Zheng D, Zou W, Lai H. A retrospective study of kidney stone recurrence in adults. J Clin Med Res. 2019;11(3):208–212. doi:10.14740/jocmr3753.
   PubMedGoogle Scholar
• Singh P, Harris PC, Sas DJ, Lieske JC. The genetics of kidney stone disease and nephrocalcinosis. Nat Rev Nephrol. 2022;18(4):224–240. doi:10.1038/s41581-021-00513-4.
   PubMed Web of Science ®Google Scholar
• Sorokin I, Mamoulakis C, Miyazawa K, Rodgers A, Talati J, Lotan Y. Epidemiology of stone disease across the world. World J Urol. 2017;35(9):1301–1320. doi:10.1007/s00345-017-2008-6.
   PubMed Web of Science ®Google Scholar
• Palsson R, Indridason OS, Edvardsson VO, Oddsson A. Genetics of common complex kidney stone disease: insights from genome-wide association studies. Urolithiasis. 2019;47(1):11–21. doi:10.1007/s00240-018-1094-2.
   PubMed Web of Science ®Google Scholar
• Peerapen P, Thongboonkerd V. Kidney stone prevention. Adv Nutr. 2023. doi:10.1016/j.advnut.2023.03.002.
   PubMed Web of Science ®Google Scholar
• Jones P, Karim Sulaiman S, Gamage KN, Tokas T, Jamnadass E, Somani BK. Do lifestyle factors including smoking, alcohol, and exercise impact your risk of developing kidney stone disease? outcomes of a systematic review. J Endourol. 2021;35(1):1–7. doi:10.1089/end.2020.0378.
   PubMed Web of Science ®Google Scholar
• Khan A. Prevalence, pathophysiological mechanisms and factors affecting urolithiasis. Int Urol Nephrol. 2018;50(5):799–806. doi:10.1007/s11255-018-1849-2.
   PubMed Web of Science ®Google Scholar
• Aizezi X, Xie L, Xie H, Li J, Shang Z, Liu C. Epidemiological and clinical characteristics of stone composition: a single-center retrospective study. Urolithiasis. 2022;50(1):37–46. doi:10.1007/s00240-021-01274-2.
   PubMed Web of Science ®Google Scholar
• Grant C, Guzman G, Stainback RP, Amdur RL, Mufarrij P. Variation in kidney stone composition within the United States. J Endourol. 2018;32(10):973–977. doi:10.1089/end.2018.0304.
   PubMed Web of Science ®Google Scholar
• Singh P, Enders FT, Vaughan LE, Bergstralh EJ, Knoedler JJ, Krambeck AE, Lieske JC, Rule AD. Stone composition among first-time symptomatic kidney stone formers in the community. Mayo Clin Proc. 2015;90(10):1356–1365. doi:10.1016/j.mayocp.2015.07.016.
   PubMed Web of Science ®Google Scholar
• Bird VY, Khan SR. How do stones form? Is unification of theories on stone formation possible? Arch Esp Urol. 2017;70:12–27.
   PubMed Web of Science ®Google Scholar
• Yoodee S, Thongboonkerd V. Bioinformatics and computational analyses of kidney stone modulatory proteins lead to solid experimental evidence and therapeutic potential. Biomed Pharmacother. 2023;159:114217. doi:10.1016/j.biopha.2023.114217.
   PubMed Web of Science ®Google Scholar
• Sassanarakkit S, Peerapen P, Thongboonkerd V. StoneMod: a database for kidney stone modulatory proteins with experimental evidence. Sci Rep. 2020;10(1):15109. doi:10.1038/s41598-020-71730-3.
   PubMed Web of Science ®Google Scholar
• Manissorn J, Fong-Ngern K, Peerapen P, Thongboonkerd V. Systematic evaluation for effects of urine pH on calcium oxalate crystallization, crystal-cell adhesion and internalization into renal tubular cells. Sci Rep. 2017;7(1):1798. doi:10.1038/s41598-017-01953-4.
   PubMed Web of Science ®Google Scholar
• Chutipongtanate S, Fong-Ngern K, Peerapen P, Thongboonkerd V. High calcium enhances calcium oxalate crystal binding capacity of renal tubular cells via increased surface annexin A1 but impairs their proliferation and healing. J Proteome Res. 2012;11(7):3650–3663. doi:10.1021/pr3000738.
   PubMed Web of Science ®Google Scholar
• Kanlaya R, Fong-Ngern K, Thongboonkerd V. Cellular adaptive response of distal renal tubular cells to high-oxalate environment highlights surface alpha-enolase as the enhancer of calcium oxalate monohydrate crystal adhesion. J Proteomics. 2013;80:55–65. doi:10.1016/j.jprot.2013.01.001.
   PubMed Web of Science ®Google Scholar
• Sutthimethakorn S, Thongboonkerd V. Effects of high-dose uric acid on cellular proteome, intracellular ATP, tissue repairing capability and calcium oxalate crystal-binding capability of renal tubular cells: implications to hyperuricosuria-induced kidney stone disease. Chem Biol Interact. 2020;331:109270. doi:10.1016/j.cbi.2020.109270.
   PubMed Web of Science ®Google Scholar
• Aggarwal KP, Narula S, Kakkar M, Tandon C. Nephrolithiasis: molecular mechanism of renal stone formation and the critical role played by modulators. Biomed Res Int. 2013;2013:292953. doi:10.1155/2013/292953.
   PubMed Web of Science ®Google Scholar
• Khan SR, Canales BK, Dominguez-Gutierrez PR. Randall’s plaque and calcium oxalate stone formation: role for immunity and inflammation. Nat Rev Nephrol. 2021;17(6):417–433. doi:10.1038/s41581-020-00392-1.
   PubMed Web of Science ®Google Scholar
• Khan SR. Reactive oxygen species as the molecular modulators of calcium oxalate kidney stone formation: evidence from clinical and experimental investigations. J Urol. 2013;189(3):803–811. doi:10.1016/j.juro.2012.05.078.
   PubMed Web of Science ®Google Scholar
• Khan SR. Reactive oxygen species, inflammation and calcium oxalate nephrolithiasis. Transl Androl Urol. 2014;3(3):256–276. doi:10.3978/j.issn.2223-4683.2014.06.04.
   PubMedGoogle Scholar
• Khan SR, Pearle MS, Robertson WG, Gambaro G, Canales BK, Doizi S, Traxer O, Tiselius H-G. Kidney stones. Nat Rev Dis Primers. 2016;2(1):16008. doi:10.1038/nrdp.2016.8.
   PubMedGoogle Scholar
• Wiener SV, Ho SP, Stoller ML. Beginnings of nephrolithiasis: insights into the past, present and future of Randall’s plaque formation research. Curr Opin Nephrol Hypertens. 2018;27(4):236–242. doi:10.1097/MNH.0000000000000414.
   PubMed Web of Science ®Google Scholar
• Rule AD, Lieske JC, Pais VM Jr. Management of Kidney Stones in 2020. JAMA. 2020;323(19):1961–1962. doi:10.1001/jama.2020.0662.
   PubMed Web of Science ®Google Scholar
• Fontenelle LF, Sarti TD. Kidney stones: treatment and prevention. Am Fam Physician. 2019;99:490–496.
   PubMed Web of Science ®Google Scholar
• Turk C, Petrik A, Sarica K, Seitz C, Skolarikos A, Straub M, Knoll T. EAU guidelines on diagnosis and conservative management of urolithiasis. Eur Urol. 2016;69(3):468–474. doi:10.1016/j.eururo.2015.07.040.
   PubMed Web of Science ®Google Scholar
• Serrell EC, Best SL. Imaging in stone diagnosis and surgical planning. Curr Opin Urol. 2022;32(4):397–404. doi:10.1097/MOU.0000000000001002.
   PubMed Web of Science ®Google Scholar
• Quhal F, Seitz C. Guideline of the guidelines: urolithiasis. Curr Opin Urol. 2021;31(2):125–129. doi:10.1097/MOU.0000000000000855.
   PubMed Web of Science ®Google Scholar
• Kozyrakis D, Zarkadas A, Katsaros I, Mourkas V, Kratiras Z. Feasibility of a single session retrograde endoscopic laser lithotripsy of two large stones located in a bifid urinary tract. Presentation of a rare case. Arch Ital Urol Androl. 2020;92(2). doi:10.4081/aiua.2020.2.117.
   PubMedGoogle Scholar
• Sabler IM, Katafigiotis I, Gofrit ON, Duvdevani M. Present indications and techniques of percutaneous nephrolithotomy: what the future holds? Asian J Urol. 2018;5(4):287–294. doi:10.1016/j.ajur.2018.08.004.
   PubMed Web of Science ®Google Scholar
• Diaz-Coranguez M, Liu X, Antonetti DA. Tight junctions in cell proliferation. Int J Mol Sci. 2019;20(23):5972. doi:10.3390/ijms20235972.
   PubMed Web of Science ®Google Scholar
• Chang J, Yan J, Li X, Liu N, Zheng R, Zhong Y. Update on the mechanisms of tubular cell injury in diabetic kidney disease. Front Med (Lausanne). 2021;8:661076. doi:10.3389/fmed.2021.661076.
   PubMed Web of Science ®Google Scholar
• Okubo K, Kurosawa M, Kamiya M, Urano Y, Suzuki A, Yamamoto K, Hase K, Homma K, Sasaki J, Miyauchi H, et al. Macrophage extracellular trap formation promoted by platelet activation is a key mediator of rhabdomyolysis-induced acute kidney injury. Nat Med. 2018;24(2):232–238. doi:10.1038/nm.4462.
   PubMed Web of Science ®Google Scholar
• An L, Wu W, Li S, Lai Y, Chen D, He Z, Chang Z, Xu P, Huang Y, Lei M, et al. Escherichia coli aggravates calcium oxalate stone formation via PPK1/Flagellin-mediated renal oxidative injury and inflammation. Oxid Med Cell Longev. 2021;2021:9949697. doi:10.1155/2021/9949697.
   PubMed Web of Science ®Google Scholar
• Dong F, Jiang S, Tang C, Wang X, Ren X, Wei Q, Tian J, Hu W, Guo J, Fu X, et al. Trimethylamine N-oxide promotes hyperoxaluria-induced calcium oxalate deposition and kidney injury by activating autophagy. Free Radical Biol Med. 2022;179:288–300. doi:10.1016/j.freeradbiomed.2021.11.010.
   PubMed Web of Science ®Google Scholar
• Vinaiphat A, Aluksanasuwan S, Manissorn J, Sutthimethakorn S, Thongboonkerd V. Response of renal tubular cells to differential types and doses of calcium oxalate crystals: integrative proteome network analysis and functional investigations. Proteomics. 2017;17:1700192. doi:10.1002/pmic.201700192.
   Web of Science ®Google Scholar
• Peerapen P, Thongboonkerd V. Effects of calcium oxalate monohydrate crystals on expression and function of tight junction of renal tubular epithelial cells. Lab Invest. 2011;91(1):97–105. doi:10.1038/labinvest.2010.167.
   PubMed Web of Science ®Google Scholar
• Peerapen P, Thongboonkerd V. P38 MAPK mediates calcium oxalate crystal-induced tight junction disruption in distal renal tubular epithelial cells. Sci Rep. 2013;3(1):1041. doi:10.1038/srep01041.
   PubMedGoogle Scholar
• Yu L, Gan X, Liu X, An R. Calcium oxalate crystals induces tight junction disruption in distal renal tubular epithelial cells by activating ROS/Akt/p38 MAPK signaling pathway. Ren Fail. 2017;39(1):440–451. doi:10.1080/0886022X.2017.1305968.
   PubMed Web of Science ®Google Scholar
• Liu Y, Tang J, Yuan J, Yao C, Hosoi K, Han Y, Yu S, Wei H, Chen G. Arsenite-induced downregulation of occludin in mouse lungs and BEAS-2B cells via the ROS/ERK/ELK1/MLCK and ROS/p38 MAPK signaling pathways. Toxicol Lett. 2020;332:146–154. doi:10.1016/j.toxlet.2020.07.010.
   PubMed Web of Science ®Google Scholar
• Liu JF, Chen PC, Ling TY, Hou CH. Hyperthermia increases HSP production in human PDMCs by stimulating ROS formation, p38 MAPK and Akt signaling, and increasing HSF1 activity. Stem Cell Res Ther. 2022;13(1):236. doi:10.1186/s13287-022-02885-1.
   PubMed Web of Science ®Google Scholar
• Lee SO, Joo SH, Kwak AW, Lee MH, Seo JH, Cho SS, Yoon G, Chae J-I, Shim J-H. Podophyllotoxin Induces ROS-Mediated apoptosis and cell cycle arrest in human colorectal cancer cells via p38 MAPK signaling. Biomol Ther (Seoul). 2021;29(6):658–666. doi:10.4062/biomolther.2021.143.
   PubMed Web of Science ®Google Scholar
• He BF, Wu YX, Hu WP, Hua JL, Han Y, Zhang J. ROS induced the Rab26 promoter hypermethylation to promote cigarette smoking-induced airway epithelial inflammation of COPD through activation of MAPK signaling. Free Radical Biol Med. 2023;195:359–370. doi:10.1016/j.freeradbiomed.2023.01.001.
   PubMed Web of Science ®Google Scholar
• Davidson PM, Cadot B. Actin on and around the nucleus. Trends Cell Biol. 2021;31(3):211–223. doi:10.1016/j.tcb.2020.11.009.
   PubMed Web of Science ®Google Scholar
• Williams TD, Rousseau A. Actin dynamics in protein homeostasis. Biosci Rep. 2022;42(9):BSR20210848. doi:10.1042/BSR20210848.
   PubMedGoogle Scholar
• Lappalainen P, Kotila T, Jegou A, Romet-Lemonne G. Biochemical and mechanical regulation of actin dynamics. Nat Rev Mol Cell Biol. 2022;23(12):836–852. doi:10.1038/s41580-022-00508-4.
   PubMed Web of Science ®Google Scholar
• Pelaseyed T, Bretscher A. Regulation of actin-based apical structures on epithelial cells. J Cell Sci. 2018;131(20):jcs221853. doi:10.1242/jcs.221853.
   PubMed Web of Science ®Google Scholar
• Svitkina TM. Actin cell cortex: structure and molecular organization. Trends Cell Biol. 2020;30(7):556–565. doi:10.1016/j.tcb.2020.03.005.
   PubMed Web of Science ®Google Scholar
• Peerapen P, Thongboonkerd V. Calcium oxalate monohydrate crystal disrupts tight junction via F-actin reorganization. Chem Biol Interact. 2021;345:109557. doi:10.1016/j.cbi.2021.109557.
   PubMed Web of Science ®Google Scholar
• Hadpech S, Peerapen P, Thongboonkerd V. Alpha-tubulin relocalization is involved in calcium oxalate-induced tight junction disruption in renal epithelial cells. Chem Biol Interact. 2022;368:110236. doi:10.1016/j.cbi.2022.110236.
   PubMed Web of Science ®Google Scholar
• Goodson HV, Jonasson EM. Microtubules and microtubule-associated proteins. Cold Spring Harb Perspect Biol. 2018;10(6):a022608. doi:10.1101/cshperspect.a022608.
   PubMed Web of Science ®Google Scholar
• Akhmanova A, Kapitein LC. Mechanisms of microtubule organization in differentiated animal cells. Nat Rev Mol Cell Biol. 2022;23(8):541–558. doi:10.1038/s41580-022-00473-y.
   PubMed Web of Science ®Google Scholar
• Yano T, Matsui T, Tamura A, Uji M, Tsukita S. The association of microtubules with tight junctions is promoted by cingulin phosphorylation by AMPK. J Cell Biol. 2013;203(4):605–614. doi:10.1083/jcb.201304194.
   PubMed Web of Science ®Google Scholar
• Yu AS. Claudins and the kidney. J Am Soc Nephrol. 2015;26(1):11–19. doi:10.1681/ASN.2014030284.
   PubMed Web of Science ®Google Scholar
• Plain A, Alexander RT. Claudins and nephrolithiasis. Curr Opin Nephrol Hypertens. 2018;27(4):268–276. doi:10.1097/MNH.0000000000000426.
   PubMed Web of Science ®Google Scholar
• Negri AL, Del Valle EE. Role of claudins in idiopathic hypercalciuria and renal lithiasis. Int Urol Nephrol. 2022;54(9):2197–2204. doi:10.1007/s11255-022-03119-2.
   PubMed Web of Science ®Google Scholar
• Hou J. Claudins and mineral metabolism. Curr Opin Nephrol Hypertens. 2016;25(4):308–313. doi:10.1097/MNH.0000000000000239.
   PubMed Web of Science ®Google Scholar
• Hou J. The yin and yang of claudin-14 function in human diseases. Ann N Y Acad Sci. 2012;1258(1):185–190. doi:10.1111/j.1749-6632.2012.06529.x.
   PubMedGoogle Scholar
• Ullah I, Murtaza K, Ammara H, Misbah BM, Riaz A, Riaz A, Shehzad W, Zahoor MY. Association study of CLDN14 variations in patients with kidney stones. Open Life Sci. 2022;17(1):81–92. doi:10.1515/biol-2021-0134.
   PubMed Web of Science ®Google Scholar
• Piedra M, Berja A, Garcia-Unzueta MT, Ramos L, Valero C, Amado JA. Rs219780 SNP of claudin 14 gene is not related to clinical expression in primary hyperparathyroidism. Clin Lab. 2015;61(09/2015):1197–1203. doi:10.7754/Clin.Lab.2015.150201.
   PubMedGoogle Scholar
• Frische S, Alexander RT, Ferreira P, Tan RSG, Wang W, Svenningsen P, Skjødt K, Dimke H. Localization and regulation of claudin-14 in experimental models of hypercalcemia. Am J Physiol Renal Physiol. 2021;320(1):F74–86. doi:10.1152/ajprenal.00397.2020.
   PubMed Web of Science ®Google Scholar
• Arteaga ME, Hunziker W, Teo AS, Hillmer AM, Mutchinick OM. Familial hypomagnesemia with hypercalciuria and nephrocalcinosis: variable phenotypic expression in three affected sisters from Mexican ancestry. Ren Fail. 2015;37(1):180–183. doi:10.3109/0886022X.2014.977141.
   PubMed Web of Science ®Google Scholar
• Weber S, Schneider L, Peters M, Misselwitz J, Ronnefarth G, Boswald M, BONZEL KE, SEEMAN T, SULÁKOVÁ T, KUWERTZ-BRöking E, et al. Novel paracellin-1 mutations in 25 families with familial hypomagnesemia with hypercalciuria and nephrocalcinosis. J Am Soc Nephrol. 2001;12(9):1872–1881. doi:10.1681/ASN.V1291872.
   PubMed Web of Science ®Google Scholar
• Sanjad SA, Hariri A, Habbal ZM, Lifton RP. A novel PCLN-1 gene mutation in familial hypomagnesemia with hypercalciuria and atypical phenotype. Pediatr Nephrol. 2007;22(4):503–508. doi:10.1007/s00467-006-0354-5.
   PubMed Web of Science ®Google Scholar
• Muller D, Kausalya PJ, Claverie-Martin F, Meij IC, Eggert P, Garcia-Nieto V, Hunziker W. A novel claudin 16 mutation associated with childhood hypercalciuria abolishes binding to ZO-1 and results in lysosomal mistargeting. Am J Hum Genet. 2003;73(6):1293–1301. doi:10.1086/380418.
   PubMed Web of Science ®Google Scholar
• Naeem M, Hussain S, Akhtar N. Mutation in the tight-junction gene claudin 19 (CLDN19) and familial hypomagnesemia, hypercalciuria, nephrocalcinosis (FHHNC) and severe ocular disease. Am J Nephrol. 2011;34(3):241–248. doi:10.1159/000330854.
   PubMed Web of Science ®Google Scholar
• Curry JN, Saurette M, Askari M, Pei L, Filla MB, Beggs MR, Rowe PSN, Fields T, Sommer AJ, Tanikawa C, et al. Claudin-2 deficiency associates with hypercalciuria in mice and human kidney stone disease. J Clin Invest. 2020;130(4):1948–1960. doi:10.1172/JCI127750.
   PubMed Web of Science ®Google Scholar
• Milatz S, Breiderhoff T. One gene, two paracellular ion channels—claudin-10 in the kidney. Pflügers Archiv - Eur J Physiol. 2017;469(1):115–121. doi:10.1007/s00424-016-1921-7.
   PubMed Web of Science ®Google Scholar
• Klar J, Piontek J, Milatz S, Tariq M, Jameel M, Breiderhoff T, Schuster J, Fatima A, Asif M, Sher M, et al. Altered paracellular cation permeability due to a rare CLDN10B variant causes anhidrosis and kidney damage. PLoS Genet. 2017;13(7):e1006897. doi:10.1371/journal.pgen.1006897.
   PubMed Web of Science ®Google Scholar
• Liu Y, Jin X, Ma Y, Sun Q, Li H, Wang K. Vinegar reduced renal calcium oxalate stones by regulating acetate metabolism in gut microbiota and crystal adhesion in rats. Int Urol Nephrol. 2022;54(10):2485–2495. doi:10.1007/s11255-022-03259-5.
   PubMed Web of Science ®Google Scholar
• Gamero-Estevez E, Andonian S, Jean-Claude B, Gupta I, Ryan AK. Temporal effects of quercetin on tight junction barrier properties and claudin expression and localization in MDCK II cells. Int J Mol Sci. 2019;20(19):20. doi:10.3390/ijms20194889.
   Web of Science ®Google Scholar
• Park HK, Jeong BC, Sung MK, Park MY, Choi EY, Kim BS, Kim HH, Kim JI. Reduction of oxidative stress in cultured renal tubular cells and preventive effects on renal stone formation by the bioflavonoid quercetin. J Urol. 2008;179(4):1620–1626. doi:10.1016/j.juro.2007.11.039.
   PubMed Web of Science ®Google Scholar
• Zhu W, Xu YF, Feng Y, Peng B, Che JP, Liu M, Zheng J-H. Prophylactic effects of quercetin and hyperoside in a calcium oxalate stone forming rat model. Urolithiasis. 2014;42(6):519–526. doi:10.1007/s00240-014-0695-7.
   PubMed Web of Science ®Google Scholar